TRIAL DATA
Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer
A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer.
Most colorectal cancers are MSS/pMMR and don't respond well to immunotherapy alone. This trial is testing whether combining immunotherapy with chemotherapy and bevacizumab can help these tumors respond. Results from this Phase 2 study will help determine whether this approach should be tested in larger trials.